Showing 6451-6460 of 8286 results for "".
- FDA Issues Complete Response Letter for UCB's Bimekizumabhttps://practicaldermatology.com/news/fda-issues-complete-response-letter-for-ucbs-bimekizumab/2461195/There’s a delay in the US regulatory review of UCB’s bimekizumab for the treatment of adults with moderate to severe plaque psoriasis. FDA has indicated it cannot approve the BLA for bimekizumab in its current form. The agency issued a Complete Response Letter (CRL) that sta
- ISHRS 2022 Practice Consensus Results: Hair Restoration Trendshttps://practicaldermatology.com/news/ishrs-2022-practice-consensus-results-hair-restoration-trends/2461192/The International Society of Hair Restoration Surgery (ISHRS) released resutls of a new member survey that found 68 percent of members performed an average of one procedure per patient in 2021 to achieve the desired hair restoration result. This represents a significant improvement, as ISHRS memb
- New Two-Year Data on Deucravacitinib Reinforce Efficacy and Safety Profile in Treatment of Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/new-two-year-on-bms-deucravacitinib-data-reinforce-efficacy-and-safety-profile-in-treatment-of-moderate-to-severe-plaque-psoriasis/2461191/Bristol Myers Squibb shared new two-year results from the POETYK PSO long-term extension (LTE) trial demonstrating durable efficacy and a consistent safety profile with deucravacitinib treatment in adult patients with moderate to severe plaque psoriasis. Clinical efficacy was maintained through u
- Indoor Tanning Ban Could Slash Melanoma Deathshttps://practicaldermatology.com/news/indoor-tanning-ban-could-slash-melanoma-deaths/2461190/An indoor tanning ban in England would reduce melanoma deaths, according to a study by University of Manchester researchers. By tracking the projected impact on the 618,000 18-year-olds living in England in 2019, the research team showed that a ban on indoor tanning would resu
- Handheld Device May Painlessly Identify Skin Cancershttps://practicaldermatology.com/news/handheld-device-may-painlessly-identify-skin-cancers/2461188/Researchers at Stevens Institute of Technology are developing a low-cost handheld device that could cut the rate of unnecessary biopsies in half and give dermatologists and other frontline physicians easy access to laboratory-grade cancer diagnostics. “We aren’t trying
- Curél Gives Back: Skincare Brand Supports Nurseshttps://practicaldermatology.com/news/curel-gives-back-skincare-brand-supports-nurses/2461187/Through Curél Cares, Curél will be donating to the American Nurses Foundation and treating several highly deserving nurses to an all-expenses-paid pampering trip to New York City. In addition, Curél will also sponsor the half-day American Nurses Associati
- DermTech Seeks to #Stickit2Melanomahttps://practicaldermatology.com/news/dermtech-seeks-to-stickit2melanoma/2461184/DermTech is bringing back its #Stickit2Melanoma campaign in honor of Melanoma and Skin Cancer Awareness Month. First launched in 2021, the campaign supports DermTech’s core mission to help end deaths from melanoma through early and reliable detection. For every
- Pathologist Survey: Melanoma Is Overdiagnosedhttps://practicaldermatology.com/news/pathologist-survey-melanoma-is-overdiagnosed/2461180/Many pathologists agree that overdiagnosis of skin cancer happens, but don’t change diagnosis behavior, according to a new study. “Overdiagnosis is the diagnosis of disease that will not harm a person in their lifetime. If melanoma is being overdiagnosed, it means that too m
- ePatch Using Electrical Field Stimulation Shows Promise for Wound Healinghttps://practicaldermatology.com/news/epatch-using-electrical-field-stimulation-shows-promise-for-wound-healing/2461175/A “smart” flexible electric patch (ePatch) developed by a collaborative team from the Terasaki Institute for Biomedical Innovation promises to address the challenges posed by existing electrical field (EF) stimulation devices for wound healing and offers many uniquely advantageous fea
- Study: Improved Survival Seen for DecisionDx-Melanoma Tested Patientshttps://practicaldermatology.com/news/study-improved-survival-seen-for-decisiondx-melanoma-tested-patients/2461168/Melanoma patients tested with DecisionDx-Melanoma plus traditional clinicopathologic factors showed improved survival compared to patients tested with only traditional clinicopathologic factors available to determine their treatment and follow-up plan, according to data presented the 18th Europea